SrasV1, PascalFrancis, Checkpoint, bibRecord, 000236

Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus

Identifieur interne : 000236 ( PascalFrancis/Checkpoint ); précédent : 000235; suivant : 000237

Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus

Auteurs : Chi-Yuan Chou [Taïwan] ; Chia-Hui Chien [Taïwan] ; Yu-San Han [Taïwan] ; Mojca Trstenjak Prebanda [Slovénie] ; Hsing-Pang Hsieh [Taïwan] ; Boris Turk [Slovénie] ; Gu-Gang Chang [Taïwan] ; XIN CHEN [Taïwan]

Source :

Biochemical pharmacology [ 0006-2952 ] ; 2008.

RBID : Pascal:08-0238691

Descripteurs français

Pascal (Inist)
- Thiopurine dérivé, Analogue, Inhibiteur, Papain, Syndrome respiratoire aigu sévère, Coronavirus, Mercaptopurine, Tioguanine, Cystéine, Anticancéreux.

English descriptors

KwdEn :
- Analog, Antineoplastic agent, Coronavirus, Cysteine, Inhibitor, Mercaptopurine, Papain, Severe acute respiratory syndrome, Thiopurine derivatives, Tioguanine.

Abstract

The papain-like protease of severe acute respiratory syndrome coronavirus (PLpro) (EC 3.4.22.46) is essential for the viral life cycle and therefore represents an important antiviral target. We have identified 6MP and 6TG as reversible and slow-binding inhibitors of SARS-CoV PLpro, which is the first report about small molecule reversible inhibitors of PLpro. The inhibition mechanism was investigated by kinetic measurements and computer docking. Both compounds are competitive, selective, and reversible inhibitors of the PLpro with K_is values ∼10 to 20 μM. A structure-function relationship study has identified the thiocarbonyl moiety of 6MP or 6TG as the active pharmacophore essential for these inhibitions, which has not been reported before. The inhibition is selective because these compounds do not exert significant inhibitory effects against other cysteine proteases, including SARS-CoV 3CLpro and several cathepsins. Thus, our results present the first potential chemical leads against SARS-CoV PLpro, which might be used as lead compounds for further optimization to enhance their potency against SARS-CoV. Both 6MP and 6TG are still used extensively in clinics, especially for children with acute lymphoblastic or myeloblastic leukemia. In light of the possible inhibition against subset of cysteine proteases, our study has emphasized the importance to study in depth these drug actions in vivo.

Affiliations:

Slovénie, Taïwan

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000287
to stream PascalFrancis, to step Curation: 000701

Links to Exploration step

Pascal:08-0238691

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus</title>
<author><name sortKey="Chou, Chi Yuan" sort="Chou, Chi Yuan" uniqKey="Chou C" first="Chi-Yuan" last="Chou">Chi-Yuan Chou</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Life Sciences and Institute of Genome Sciences, National Yang-Ming University</s1>
<s2>Taipei 112</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Taipei 112</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chien, Chia Hui" sort="Chien, Chia Hui" uniqKey="Chien C" first="Chia-Hui" last="Chien">Chia-Hui Chien</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35 Keyan Rd</s1>
<s2>Zhunan town, Miaoli County 350</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Zhunan town, Miaoli County 350</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Han, Yu San" sort="Han, Yu San" uniqKey="Han Y" first="Yu-San" last="Han">Yu-San Han</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35 Keyan Rd</s1>
<s2>Zhunan town, Miaoli County 350</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Zhunan town, Miaoli County 350</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Trstenjak Prebanda, Mojca" sort="Trstenjak Prebanda, Mojca" uniqKey="Trstenjak Prebanda M" first="Mojca" last="Trstenjak Prebanda">Mojca Trstenjak Prebanda</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Biochemistry, Molecular and Structural Biology, J. Stefan Institute, Jamova 39</s1>
<s2>1000 Ljubljana</s2>
<s3>SVN</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Slovénie</country>
<wicri:noRegion>1000 Ljubljana</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hsieh, Hsing Pang" sort="Hsieh, Hsing Pang" uniqKey="Hsieh H" first="Hsing-Pang" last="Hsieh">Hsing-Pang Hsieh</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35 Keyan Rd</s1>
<s2>Zhunan town, Miaoli County 350</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Zhunan town, Miaoli County 350</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Turk, Boris" sort="Turk, Boris" uniqKey="Turk B" first="Boris" last="Turk">Boris Turk</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Biochemistry, Molecular and Structural Biology, J. Stefan Institute, Jamova 39</s1>
<s2>1000 Ljubljana</s2>
<s3>SVN</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Slovénie</country>
<wicri:noRegion>1000 Ljubljana</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chang, Gu Gang" sort="Chang, Gu Gang" uniqKey="Chang G" first="Gu-Gang" last="Chang">Gu-Gang Chang</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Life Sciences and Institute of Genome Sciences, National Yang-Ming University</s1>
<s2>Taipei 112</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Taipei 112</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Xin Chen" sort="Xin Chen" uniqKey="Xin Chen" last="Xin Chen">XIN CHEN</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35 Keyan Rd</s1>
<s2>Zhunan town, Miaoli County 350</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Zhunan town, Miaoli County 350</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0238691</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0238691 INIST</idno>
<idno type="RBID">Pascal:08-0238691</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000287</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000701</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000236</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000236</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus</title>
<author><name sortKey="Chou, Chi Yuan" sort="Chou, Chi Yuan" uniqKey="Chou C" first="Chi-Yuan" last="Chou">Chi-Yuan Chou</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Life Sciences and Institute of Genome Sciences, National Yang-Ming University</s1>
<s2>Taipei 112</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Taipei 112</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chien, Chia Hui" sort="Chien, Chia Hui" uniqKey="Chien C" first="Chia-Hui" last="Chien">Chia-Hui Chien</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35 Keyan Rd</s1>
<s2>Zhunan town, Miaoli County 350</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Zhunan town, Miaoli County 350</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Han, Yu San" sort="Han, Yu San" uniqKey="Han Y" first="Yu-San" last="Han">Yu-San Han</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35 Keyan Rd</s1>
<s2>Zhunan town, Miaoli County 350</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Zhunan town, Miaoli County 350</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Trstenjak Prebanda, Mojca" sort="Trstenjak Prebanda, Mojca" uniqKey="Trstenjak Prebanda M" first="Mojca" last="Trstenjak Prebanda">Mojca Trstenjak Prebanda</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Biochemistry, Molecular and Structural Biology, J. Stefan Institute, Jamova 39</s1>
<s2>1000 Ljubljana</s2>
<s3>SVN</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Slovénie</country>
<wicri:noRegion>1000 Ljubljana</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hsieh, Hsing Pang" sort="Hsieh, Hsing Pang" uniqKey="Hsieh H" first="Hsing-Pang" last="Hsieh">Hsing-Pang Hsieh</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35 Keyan Rd</s1>
<s2>Zhunan town, Miaoli County 350</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Zhunan town, Miaoli County 350</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Turk, Boris" sort="Turk, Boris" uniqKey="Turk B" first="Boris" last="Turk">Boris Turk</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Biochemistry, Molecular and Structural Biology, J. Stefan Institute, Jamova 39</s1>
<s2>1000 Ljubljana</s2>
<s3>SVN</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Slovénie</country>
<wicri:noRegion>1000 Ljubljana</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chang, Gu Gang" sort="Chang, Gu Gang" uniqKey="Chang G" first="Gu-Gang" last="Chang">Gu-Gang Chang</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Life Sciences and Institute of Genome Sciences, National Yang-Ming University</s1>
<s2>Taipei 112</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Taipei 112</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Xin Chen" sort="Xin Chen" uniqKey="Xin Chen" last="Xin Chen">XIN CHEN</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35 Keyan Rd</s1>
<s2>Zhunan town, Miaoli County 350</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Zhunan town, Miaoli County 350</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Biochemical pharmacology</title>
<title level="j" type="abbreviated">Biochem. pharmacol.</title>
<idno type="ISSN">0006-2952</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Biochemical pharmacology</title>
<title level="j" type="abbreviated">Biochem. pharmacol.</title>
<idno type="ISSN">0006-2952</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analog</term>
<term>Antineoplastic agent</term>
<term>Coronavirus</term>
<term>Cysteine</term>
<term>Inhibitor</term>
<term>Mercaptopurine</term>
<term>Papain</term>
<term>Severe acute respiratory syndrome</term>
<term>Thiopurine derivatives</term>
<term>Tioguanine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Thiopurine dérivé</term>
<term>Analogue</term>
<term>Inhibiteur</term>
<term>Papain</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Coronavirus</term>
<term>Mercaptopurine</term>
<term>Tioguanine</term>
<term>Cystéine</term>
<term>Anticancéreux</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The papain-like protease of severe acute respiratory syndrome coronavirus (PLpro) (EC 3.4.22.46) is essential for the viral life cycle and therefore represents an important antiviral target. We have identified 6MP and 6TG as reversible and slow-binding inhibitors of SARS-CoV PLpro, which is the first report about small molecule reversible inhibitors of PLpro. The inhibition mechanism was investigated by kinetic measurements and computer docking. Both compounds are competitive, selective, and reversible inhibitors of the PLpro with K<sub>is</sub>
 values ∼10 to 20 μM. A structure-function relationship study has identified the thiocarbonyl moiety of 6MP or 6TG as the active pharmacophore essential for these inhibitions, which has not been reported before. The inhibition is selective because these compounds do not exert significant inhibitory effects against other cysteine proteases, including SARS-CoV 3CLpro and several cathepsins. Thus, our results present the first potential chemical leads against SARS-CoV PLpro, which might be used as lead compounds for further optimization to enhance their potency against SARS-CoV. Both 6MP and 6TG are still used extensively in clinics, especially for children with acute lymphoblastic or myeloblastic leukemia. In light of the possible inhibition against subset of cysteine proteases, our study has emphasized the importance to study in depth these drug actions in vivo.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0006-2952</s0>
</fA01>
<fA02 i1="01"><s0>BCPCA6</s0>
</fA02>
<fA03 i2="1"><s0>Biochem. pharmacol.</s0>
</fA03>
<fA05><s2>75</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CHOU (Chi-Yuan)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CHIEN (Chia-Hui)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HAN (Yu-San)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>TRSTENJAK PREBANDA (Mojca)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HSIEH (Hsing-Pang)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>TURK (Boris)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>CHANG (Gu-Gang)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>XIN CHEN</s1>
</fA11>
<fA14 i1="01"><s1>Department of Life Sciences and Institute of Genome Sciences, National Yang-Ming University</s1>
<s2>Taipei 112</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35 Keyan Rd</s1>
<s2>Zhunan town, Miaoli County 350</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Biochemistry, Molecular and Structural Biology, J. Stefan Institute, Jamova 39</s1>
<s2>1000 Ljubljana</s2>
<s3>SVN</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>1601-1609</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>1418</s2>
<s5>354000183399200040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>47 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0238691</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Biochemical pharmacology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The papain-like protease of severe acute respiratory syndrome coronavirus (PLpro) (EC 3.4.22.46) is essential for the viral life cycle and therefore represents an important antiviral target. We have identified 6MP and 6TG as reversible and slow-binding inhibitors of SARS-CoV PLpro, which is the first report about small molecule reversible inhibitors of PLpro. The inhibition mechanism was investigated by kinetic measurements and computer docking. Both compounds are competitive, selective, and reversible inhibitors of the PLpro with K<sub>is</sub>
 values ∼10 to 20 μM. A structure-function relationship study has identified the thiocarbonyl moiety of 6MP or 6TG as the active pharmacophore essential for these inhibitions, which has not been reported before. The inhibition is selective because these compounds do not exert significant inhibitory effects against other cysteine proteases, including SARS-CoV 3CLpro and several cathepsins. Thus, our results present the first potential chemical leads against SARS-CoV PLpro, which might be used as lead compounds for further optimization to enhance their potency against SARS-CoV. Both 6MP and 6TG are still used extensively in clinics, especially for children with acute lymphoblastic or myeloblastic leukemia. In light of the possible inhibition against subset of cysteine proteases, our study has emphasized the importance to study in depth these drug actions in vivo.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Thiopurine dérivé</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Thiopurine derivatives</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Derivado de la tiopurina</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Analogue</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Analog</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Análogo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Inhibiteur</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Inhibitor</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Inhibidor</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Papain</s0>
<s2>FE</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Papain</s0>
<s2>FE</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Papain</s0>
<s2>FE</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Mercaptopurine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Mercaptopurine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Mercaptopurina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Tioguanine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Tioguanine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tioguanina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Cystéine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Cysteine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Cisteína</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Cysteine endopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cysteine endopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Cysteine endopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Pathologie de l'appareil respiratoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Pathologie des poumons</s0>
<s5>38</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Antimétabolite</s0>
<s5>40</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Antimetabolic</s0>
<s5>40</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Antimetabólito</s0>
<s5>40</s5>
</fC07>
<fC07 i1="13" i2="X" l="FRE"><s0>Dérivé de la purine</s0>
<s5>41</s5>
</fC07>
<fC07 i1="13" i2="X" l="ENG"><s0>Purine derivatives</s0>
<s5>41</s5>
</fC07>
<fC07 i1="13" i2="X" l="SPA"><s0>Purina derivado</s0>
<s5>41</s5>
</fC07>
<fC07 i1="14" i2="X" l="FRE"><s0>Aminoacide soufré</s0>
<s5>42</s5>
</fC07>
<fC07 i1="14" i2="X" l="ENG"><s0>Sulfur containing aminoacid</s0>
<s5>42</s5>
</fC07>
<fC07 i1="14" i2="X" l="SPA"><s0>Aminoácido azufrado</s0>
<s5>42</s5>
</fC07>
<fC07 i1="15" i2="X" l="FRE"><s0>Thiol</s0>
<s5>43</s5>
</fC07>
<fC07 i1="15" i2="X" l="ENG"><s0>Thiol</s0>
<s5>43</s5>
</fC07>
<fC07 i1="15" i2="X" l="SPA"><s0>Tiol</s0>
<s5>43</s5>
</fC07>
<fN21><s1>154</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Slovénie</li>
<li>Taïwan</li>
</country>
</list>
<tree><country name="Taïwan"><noRegion><name sortKey="Chou, Chi Yuan" sort="Chou, Chi Yuan" uniqKey="Chou C" first="Chi-Yuan" last="Chou">Chi-Yuan Chou</name>
</noRegion>
<name sortKey="Chang, Gu Gang" sort="Chang, Gu Gang" uniqKey="Chang G" first="Gu-Gang" last="Chang">Gu-Gang Chang</name>
<name sortKey="Chien, Chia Hui" sort="Chien, Chia Hui" uniqKey="Chien C" first="Chia-Hui" last="Chien">Chia-Hui Chien</name>
<name sortKey="Han, Yu San" sort="Han, Yu San" uniqKey="Han Y" first="Yu-San" last="Han">Yu-San Han</name>
<name sortKey="Hsieh, Hsing Pang" sort="Hsieh, Hsing Pang" uniqKey="Hsieh H" first="Hsing-Pang" last="Hsieh">Hsing-Pang Hsieh</name>
<name sortKey="Xin Chen" sort="Xin Chen" uniqKey="Xin Chen" last="Xin Chen">XIN CHEN</name>
</country>
<country name="Slovénie"><noRegion><name sortKey="Trstenjak Prebanda, Mojca" sort="Trstenjak Prebanda, Mojca" uniqKey="Trstenjak Prebanda M" first="Mojca" last="Trstenjak Prebanda">Mojca Trstenjak Prebanda</name>
</noRegion>
<name sortKey="Turk, Boris" sort="Turk, Boris" uniqKey="Turk B" first="Boris" last="Turk">Boris Turk</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000236 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000236 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:08-0238691
   |texte=   Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus

Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri